estriol has been researched along with Melanoma in 3 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Estriol was more potent, with the maximal blockade occurring at approximately 0." | 5.27 | Inhibition of imidazole-induced tyrosinase activity by estradiol and estriol in cultured B16/C3 melanoma cells. ( Blackmon, B; Carland, KA; Kline, EL; Smith, TJ, 1988) |
| " estrone, 17-beta-estradiol and estriol, was studied in a melanoma cell line producing a tissue-type plasminogen activator (t-PA)." | 3.67 | Estrogen regulation of tissue plasminogen activator in a human melanoma cell line. ( Astedt, B; Kjaeldgaard, A; Larsson, B, 1986) |
| " In the present study, we have compared the pharmacokinetic profiles and metabolism of 2-MeOE2 and its sulphamoylated derivative, 2-methoxyoestradiol-bis-sulphamate (2-MeOE2bisMATE), in adult female rats." | 1.32 | Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. ( Chander, SK; Ireson, CR; Leese, MP; Newman, SP; Parish, D; Perera, S; Potter, BV; Purohit, A; Reed, MJ; Smith, AC, 2004) |
| "Estriol was more potent, with the maximal blockade occurring at approximately 0." | 1.27 | Inhibition of imidazole-induced tyrosinase activity by estradiol and estriol in cultured B16/C3 melanoma cells. ( Blackmon, B; Carland, KA; Kline, EL; Smith, TJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ireson, CR | 1 |
| Chander, SK | 1 |
| Purohit, A | 1 |
| Perera, S | 1 |
| Newman, SP | 1 |
| Parish, D | 1 |
| Leese, MP | 1 |
| Smith, AC | 1 |
| Potter, BV | 1 |
| Reed, MJ | 1 |
| Kjaeldgaard, A | 1 |
| Larsson, B | 1 |
| Astedt, B | 1 |
| Kline, EL | 1 |
| Smith, TJ | 1 |
| Carland, KA | 1 |
| Blackmon, B | 1 |
3 other studies available for estriol and Melanoma
| Article | Year |
|---|---|
Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
Topics: 2-Methoxyestradiol; Administration, Oral; Animals; Biological Availability; Breast Neoplasms; Dose-R | 2004 |
Estrogen regulation of tissue plasminogen activator in a human melanoma cell line.
Topics: Cell Line; Depression, Chemical; Dose-Response Relationship, Drug; Estradiol; Estriol; Estrogens; Es | 1986 |
Inhibition of imidazole-induced tyrosinase activity by estradiol and estriol in cultured B16/C3 melanoma cells.
Topics: Animals; Catechol Oxidase; Cell Division; Dactinomycin; Dose-Response Relationship, Drug; Enzyme Ind | 1988 |